<DOC>
	<DOCNO>NCT02003573</DOCNO>
	<brief_summary>Dose Escalation ( MTD Finding ) Phase : To investigate maximum tolerate dose ( MTD ) , safety pharmacokinetics different volasertib administration schedule combination decitabine previously untreated AML patient &gt; = 65 year age consider ineligible standard intensive therapy , patient relapse refractory AML regardless prior treatment status . MTD Extension Phase : To collect additional data safety , efficacy pharmacokinetics volasertib combination decitabine previously untreated patient AML &gt; = 65 year age consider ineligible standard intensive therapy .</brief_summary>
	<brief_title>Volasertib + Decitabine Patients With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion criterion : 1 . Dose Escalation Phase : patient previously untreated AML , relapse refractory AML regardless prior treatment status . 2 . MTD Extension Phase : previously untreated AML ( prior treatment MDS allow ) . 3 . Age &gt; = 65 year . 4 . Previously untreated patient must ineligible receive standard intensive therapy time enrolment , opinion investigator base document medical reason . 5 . Histologically cytologically confirm AML ( except APL , FAB subtype M3 ) accord WHO classification . 6 . Eastern cooperative oncology group ( ECOG ) performance score = &lt; 1 screening . 7 . Signed date write informed consent start date Screening Visit accordance GCP local legislation . Exclusion criterion : 1 . MTD Extension Phase : Prior chemotherapy AML ( except hydroxyurea ) . Patients receive treatment hydroxyurea order reduce high WBC count 28 day ( cumulative ) ; discontinuation hydroxyurea least one day prior study treatment require . Please note prior therapy MDS allow . 2 . Acute promyelocytic leukemia ( APL , FAB subtype M3 ) , accord WHO classification . 3 . Hypersensitivity trial drug . 4 . Other malignancy currently require active therapy ( except hormonal/antihormonal treatment , e.g . prostate breast cancer ) . 5 . Known clinical central nervous system ( CNS ) symptom deem investigator related leukemic CNS involvement . 6 . QTcF &gt; 470 m , calculate mean value triplicate take least 2 minute apart baseline QTcF prolongation deem clinically relevant investigator . 7 . Baseline LVEF &lt; 45 % low limit institutional normal range . 8 . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) &gt; 2.5 x upper limit normal ( ULN ) . Patients elevate liver enzyme ( ) due leukemic involvement allow = 5 x ULN . 9 . Total bilirubin &gt; 1.5 x ULN . For patient Gilbert 's syndrome elevation due hepatic infiltrate , total bilirubin must &lt; 4 x ULN . 10 . Creatinine clearance ( CLcr ) &lt; 30 ml/min ( estimate creatinine clearance CockcroftGault ( CG ) equation . 11 . Severe illness organ dysfunction involve kidney , liver organ system , include active uncontrolled infection , opinion investigator precludes treatment decitabine would interfere evaluation safety study treatment . 12 . Presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure New York Heart Association ( NYHA ) Classification 3 , unstable angina poorly control arrhythmia determine investigator . Myocardial infarction within 6 month prior study entry . 13 . Significant concurrent psychiatric disorder social situation accord investigator 's judgment would compromise patient 's safety compliance , interfere consent , study participation , interpretation study result . 14 . Patients systemic fungal , bacterial , viral , infection control . 15 . Contraindications decitabine treatment accord manufacturer 's prescribe information provide ISF . 16 . Female patient childbearing potential sexually active unwilling use medically acceptable method contraception trial minimum 6 month completion study treatment . 17 . Male patient partner childbearing potential unwilling use condom combination second medically acceptable method contraception trial minimum 6 month completion study treatment . 18 . Pregnant breast feeding patient . 19 . Treatment investigational drug within 2 week administration first study medication dose within less five half live investigational drug treatment present trial drug , whichever short , / persistence toxicity prior antileukemic therapy deem clinically relevant . 20 . Prior treatment Plk inhibitor volasertib treatment clinical trial use Plk inhibitory compound .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>